EI
CBMG

EAM Investors’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

EAM Investors’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-30,450
Closed -$958K – 402
2015
Q1 		$958K Buy
+30,450
New +$823K 0.11% 305

Other funds holding CBMG

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

EAM Investors's CBMG Position: Q2 2015 in Review

EAM Investors sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q2 2015, closing a stake of 30,450 shares — an estimated $958K sold.

EAM Investors first reported a position in CBMG in Q1 2015 and held it in 1 quarter. The position peaked at $958K in Q1 2015. 45 funds tracked by Wall St. Rank hold CBMG as of Q2 2015.

  • EAM Investors reported no remaining Cellular Biomedicine Group, Inc. position as of Q2 2015 after selling out during the quarter.
  • EAM Investors sold 30,450 Cellular Biomedicine Group, Inc. shares in Q2 2015, an estimated $958K.
  • EAM Investors first reported a position in Cellular Biomedicine Group, Inc. in Q1 2015 and held it in 1 quarter.
  • EAM Investors's Cellular Biomedicine Group, Inc. position peaked at $958K in Q1 2015.
  • 45 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q2 2015.

Based on EAM Investors's 13F filing for Q2 2015, filed 13 Aug 2015.